| This fund tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. |
FUND BASICS
| Category |
US Equities |
| Fund Sponsor |
US Bancorp |
| Website |
www.loncarfunds.com/ |
| Inception date |
Oct 13, 2015 |
| Assets (mns) |
$7 |
| Currency |
USD |
| Expense ratio |
79 bp |
| Distributions |
Annually |
FUND STRUCTURE
| Regulation |
Open-End Investment Company |
| Custodian |
|
| Weighting |
Equal |
| Index replication |
|
| Uses derivatives |
No |
| Options available |
No |
CONSTITUENT BREAKDOWN
| No. of constituents |
63 |
| Wgt avg mkt cap (mns) |
$7,565 |
| Large cap (>$10bn) |
11.4% |
| Mid cap ($2-10bn) |
15.4% |
| Small cap (<$2bn) |
73.2% |
| Developed mkts |
100.0% |
| Emerging mkts |
0.0% |
TOP TEN HOLDINGS
| CASH & OTHER |
100.0 % |
Total |
100.0 % |
TOP COUNTRY EXPOSURE
 |
|
0.0 % |
Standardized Annual Returns (thru June 30)
| Year-to-date |
1 year |
5 years |
10 years |
Since Incep. |
| -26.7% |
-33.2% |
-18.4% |
-- |
-9.1% |
Market Correlations
| versus... |
Beta |
R-squared |
| S&P500 |
1.20 |
34% |
| MSCI EAFE |
0.97 |
23% |
| MSCI Emg. Mkts. |
0.66 |
12% |
Technical Indicators
| Recent close |
$9.02 |
| 30d moving avg. |
$9.28 |
| Annualized volatility |
32.9% |
| Short interest (ETF) |
0.9% |
| Short interest (Underlying) |
4.9% |
| Relative strength (RSI) |
44 |
Liquidity measures
| Avg. volume (thou.) |
3 |
| Turnover |
0.4% |
| Bid/Ask (% of price) |
1.00% |
| ADV underlying (mns) |
$2,553 |
 |
There were no matches found with other funds under coverage. |
Content on this tab for subscribers only**
| |
2020 |
2021 |
2022 |
2023 |
2024 |
2025E |
2026E |
| Sales per share |
** |
** |
** |
** |
** |
** |
** |
| Earnings per share |
** |
** |
** |
** |
** |
** |
** |
Dividends per share  |
** |
** |
** |
** |
** |
** |
** |
| Book value per share |
** |
** |
** |
** |
** |
** |
** |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Sales per share growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| EPS growth |
|
**% |
**% |
**% |
**% |
**% |
**% |
| Long term EPS growth est. |
**% |
|
Debt-to-equity |
**x |
| Asset turnover |
**% |
|
Assets-to-equity |
**x |
Revision activity*
|
| *Six months ago = 100 |
Compound annual growth rates
|
Content on this tab for subscribers only
| |
2024 |
2025E |
2026E |
| Price-to-sales |
** |
** |
** |
| Price-to-earnings |
** |
** |
** |
| Price-to-cash flow |
** |
** |
** |
| Price-to-growth |
** |
** |
** |
| Price-to-book value |
** |
** |
** |
| Yield |
** |
** |
** |
AVOID |
| Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant. |
| Calculation of ALTAR Score™ |
| Avg. Return on Equity |
-61.6 |
% |
| Divided by: Fwd. P/BV |
1.9 |
x |
| Less: Expense ratio |
79 |
bp |
| Equals: ALTAR Score |
-33.0 |
% |
|
| More information on ALTAR Score™ |
|
|
|
Fundamentals